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ABSTRACT
Background. Genetic sequencing and precision oncology
have supported clinical breakthroughs but depend upon
access to vast arrays of research specimens and data.
One way for academic medical centers to fund such
infrastructure and research is “commercialization” of
access to specimens and data to industry. Here we
explore patient and clinician perspectives regarding can-
cer specimen and data commercialization with the goal
of improving such processes in the future.
Materials and Methods. This qualitative analysis was embed-
ded within a prospective precision oncology sequencing study
of adults with head and neck cancer. Via semistructured
dyadic interviews with patients with cancer and their doctors,
we assessed understanding and concerns regarding potential
commercialization, opinions regarding investment of profits,
and perspectives regarding the return of information directly
to participants from industry.
Results. Several patient- and clinician-participants did not
understand that the consent form already permitted commer-
cialization of patient genetic data and expressed concerns
regarding who would profit from the data, how profits would
be used, and privacy and access. Patients were generally more
comfortable with commercialization than clinicians. Many
patients and clinicians were comfortable with investing profits
back into research, but clinicians were more interested in
investment in head and neck cancer research specifically.
Patients generally supported potential return-of-results from
a private entity, but their clinicians were more skeptical.
Conclusion. Our results illustrate the limitations of manda-
tory disclosures in the informed consent process. The voices
of both patients and their doctors are critical to mitigate
violations of privacy and a degradation of trust as stake-
holders negotiate the terms of academic and commercial
engagement. The Oncologist 2020;25:620–626
Implications for Practice: Further education is needed regarding how and why specimens and data in precision oncology
research may be commercialized for both patients and providers alike. This process will require increased transparency,
comprehension, and engagement of involved stakeholders.
INTRODUCTION
Ongoing advances in next-generation genetic sequencing
and precision oncology have yielded encouraging break-
throughs in our understanding and treatment of cancer
[1]. But such advances in “precision medicine” depend
upon researchers having access to vast arrays of genetic
and corresponding clinical and phenotypic data to enable
scientific discovery [2]. The breadth of such data sets
permits an otherwise inaccessible depth of analysis that
can ultimately translate into substantive improvements in
cancer discovery, patient survival, and quality of life [1,
3]. Accordingly, with the increasing utility of emerging
technologies and methodological approaches, the cost of
translational cancer research programs continues to
escalate.
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Medical Ethics
Researchers, and the databanks and biobanks upon which
they rely, require steady streams of funding, the sources of
which are often unreliable and inconsistent [4]. One possible
solution to these dual needs is to “commercialize” patient or
research participant (“contributor”) specimens or data, a pro-
cess in which an academic medical center (AMC) sells access
to specimens or data to a company for profit [5]. But such
commercialization raises a number of both practical and ethi-
cal challenges relating to contributor consent and the appro-
priate uses of such profits.
Biospecimens and health data are generally regulated by
how they are originally collected, differentiating between
those from patients, research participants, and customers.
However, the combination of inexpensive and accessible
direct-to-consumer personal genetic testing; growing public
interest in ancestry, wellness, and genetic health information;
and an increased focus on precision medicine and big data
analytics has incentivized increased sharing of genetic data
between AMCs and commercial entities [6, 7]. This sharing, in
turn, blurs the original distinctions between data collectors.
Such data sharing might be necessary for achieving prom-
ising (and profitable) medical and technological advances.
Yet some contributors are uncomfortable with the sale of
their specimens or data from an AMC to a private company.
Failure to be sufficiently transparent could therefore lead to
a degradation of trust and decrease in willingness to donate
specimens and data to research in the future [8].
Recent changes to the Federal Policy for the Protection
of Human Subjects (the “Common Rule”) now require that
regulated researchers notify potential participants if their
biospecimens may be shared for commercial profit. However,
these regulations only apply to biospecimens that are “iden-
tifiable” (the definition of which is still in debate) and do not
apply to the data derived from such specimens [9]. Although
this revision provides additional disclosure obligations for
regulated researchers, disclosure only achieves an additional
layer of protection if participants actually read and compre-
hend such information [10]. Yet we know that participants
already have substantial difficulty comprehending complex
informed consent forms because of poor readability, thera-
peutic misconception, and other factors [11–14]. To simply
add a statement regarding data commercialization to a con-
sent form, as required by the regulations, may be insufficient
to ensure that consent is truly informed.
Critical questions therefore persist: what do participants
actually understand from disclosures regarding commerciali-
zation of their specimens and data? What specific concerns
do participants and their referring clinicians have regarding
such commercialization? And, although the public is gener-
ally assuaged by knowing funds earned from the commercial-
ization of their specimens will be used for further research
[5], what kinds of research are contributors most interested
in supporting? Last, would it be appropriate for the private
entity to return additional results (such as ancestry informa-
tion) directly to participants?
To better understand both patient and clinician perspec-
tives on cancer specimen and data commercialization, we
conducted dydactic interviews of patients participating in a
prospective precision medicine cancer sequencing study
along with their referring cancer doctors. Our goal was to
inform how researchers at AMCs can better design and
implement a transparent consent process for biospecimen
and health data sharing and commercialization.
MATERIALS AND METHODS
This qualitative ethical inquiry was embedded within a pro-
spective precision oncology sequencing study of adult
patients with biopsy-proven cancer of the head and neck at
an National Cancer Institute–designated academic compre-
hensive cancer center. Dyadic interviews were conducted
throughout 2018. This research was approved by the Univer-
sity of Michigan Medical School IRB.
Overarching Study Design
The overarching study, “Developing Precision Medicine Pro-
tocols for Head and Neck Cancer Michigan Otolaryngology
Sequencing Center (MiOtoSeq),” is an institutional review
board–approved precision medicine study in the Michigan
Medicine Department of Otolaryngology–Head and Neck
Surgery [15]. Patients diagnosed with head and neck cancer
were offered enrollment via a counseling and form-based
informed consent process, followed by targeted genomic
sequencing. We then nested a multimethod empirical ethics
protocol (conducting surveys and semistructured interviews
with both patients and their clinicians) within the MiOtoSeq
study to explore why patients chose to participate in the
precision oncology sequencing, the role that their clinicians
played in enrollment, and a variety of other topics of ethical
and legal interest. Here, we present results regarding partic-
ipant and clinician perspectives on the potential commer-
cialization of patient genetic data.
Interviews
A purposive subset of MiOtoSeq participants were sampled,
based on diversity in demographic, clinical, and oncological
factors. Interviews were conducted by trained researchers
using a semistructured interview guide to ensure consis-
tency while still permitting flexibility to thoroughly explore
each patient’s responses [16]. Interviews lasted approxi-
mately 1 hour and were audio recorded, professionally
transcribed, and de-identified. All data were maintained in
a secure, cross-platform data management system.
Participants were asked about their feelings regarding
their genetic data being “commercialized” or sold to a private
company, such as a pharmaceutical company, for their own
use without any identifying information. We then queried
patient- and clinician-participant feelings regarding investing
profits back into cancer research or University of Michigan
research more broadly. Last we asked about patient- and
clinician-participant feelings regarding return of information
from a private company directly (see Table 1).
Responses from 14 interviews are included: 8 patients
and 6 clinicians (1 clinician provided care to 2 patients and
another clinician’s responses were excluded from quotation
as he is an author on this analysis [A.G.S.]). Recruitment
was complete once thematic saturation was reached [16].
Two members of the study team (C.D.K., K.S.-B.) indepen-
dently read the interview transcripts to inductively develop
an iterative coding schema [16, 17]. Transcripts were then
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double coded (K.S.-B., C.D.K.) and discrepancies were recon-
ciled (A.G.S.). Additional details regarding the methodology
of this qualitative inquiry are available elsewhere [18].
RESULTS
We had five male and three female patient-participants,
seven of whom were white, with an average age of 54, and a
variety of prognoses (with 10-year estimated mortality rang-
ing from 10% to 95%) [19, 20]. We had four male and two
female clinician-participants, all doctors of medicine, with a
median of 9 years (range 2–11) in faculty practice. We will
use she/her for presentation of all results to enhance privacy
for participants.
Overall, we found that several patient- and clinician-
participants did not understand that the consent form
already permitted commercialization of patient genetic data.
Both groups also expressed concerns regarding who would
profit from the data, how profits would be used, and privacy
and access issues. Patients were generally more comfortable
with commercialization than clinicians. Most patients and cli-
nicians were comfortable with investing profits back into
research, but clinicians were more interested in the invest-
ment in head and neck cancer research specifically. Many
patients supported potential return-of-results from a private
entity, but their clinicians were more skeptical.
Confusion Regarding the Scope of Informed Consent
Our first thematic finding was that several patient- and
clinician-participants in our interviews did not realize that
the MiOtoSeq informed consent disclosed potential future
commercialization of genetic data. Of note, this was not
one of our initial hypotheses but was rather an emergent
finding that we further explored through the interviews.
The MiOtoSeq informed consent process included clinicians
presenting their patients with the opportunity to partici-
pate in the research, including a general overview of what
participation would entail, and providing them with a
15-page consent form with further details. If the patient
was interested in participation, they reviewed relevant
details in person with a study coordinator. The overarching
MiOtoSeq consent form met current regulatory standards
for the disclosure of commercialization and contained (see
Table 2).
Despite the above disclosure, when asked about her
feelings regarding data commercialization, one patient-
participant stated: “…I hope you don’t, because I don’t think
you said you would, or did you? I don’t remember the con-
sent form” (P04). This participant not only did not recall such
a disclosure, but in fact recalled the opposite to be true—
she followed up that if she found out her data had been
commercialized “I’d get my lawyer because you promised
that none of my personal information would be given to
anyone outside the university!” (P04). Another patient-
participant agreed that “all of a sudden, my information is
going for things…that I wasn’t originally told about” (P06),
but also admitted that she did not actually recall what the
informed consent form said.
In agreement, the clinician of the patient who threatened
to get her lawyer wondered why researchers had not already
sent “something out and find out if people would opt
out…”(C04/06)? Another clinician stated that she “wouldn’t
be excited about” the possibility of commercialization if she
were a patient and understood “that there would have to be
some language in the consent form that this could poten-
tially occur…” (C08). A third admitted she was “less comfort-
able” about the possibility of commercialization and wanted
to “verify with the patients prospectively” that they under-
stood that that was a possibility (C11).
Concerns with the Commercialization of Patient Data
Participants also expressed several concerns regarding the
commercialization of genetic data, most notably regarding
Table 1. Interview questions on the commercialization of genetic data
Topic Questions to clinicians Questions to patients
Selling de-identified
genetic data to private
companies
In the informed consent form we told your
patient that their genetic data might be used by
the [university] for future research. Tell me
about how you would feel about referring your
patients to this research study if we were
planning on selling their genetic data to private
companies, such as pharmaceutical companies,
for their own use without any patient identifying
information?
In the informed consent form we told you
that your genetic data might be used by the
[university] for future research. How would
you feel if we also asked your permission to
sell your data to private companies, such as
pharmaceutical companies, for their own use
without any of your identifying information?
Investing profits in cancer
research
How would you feel if we invested any profits
that we made from selling your patients’ genetic
data back into advancing our own research into
treating and curing cancer?
How would you feel if we invested any profits
that we made from selling your genetic data
back into advancing our own research into




What about using any profits to support
[university] research generally?
What about using any profits to support
[university] research generally?
Receiving personal info
(e.g., ancestry data) from
private companies
How would you feel if your patients got some
information in return from the private company
directly—such as ancestry information or other
genetic information we would not otherwise
give them?
How would you feel if you got some
information in return from the private
company directly—such as ancestry
information or other genetic information we
would not otherwise give you?
Differences between the patient and clinician questions are bolded.
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(a) who will profit and how such profits will be used and (b)
privacy and access to data.
When discussing concerns regarding who will profit and
how such profits will be used, one patient-participant said
she would object to profits being used to “line some doctors’
[or] administrators’ pockets…” (P04). Another patient said
that if the funds were used to make a profit “that doesn’t sit
well…I’d rather you guys not make a profit off of research on
me” (P06). Several of our clinician-participants were also
skeptical, with one observing that “…the waters probably get
very muddy…with regard to who ends up profiting from
those types of studies” (C11) and another stating that “…if
the money is going to profit any one person…then it
becomes ethically problematic” (C07).
A second area of concern for participants was ensuring
data privacy and control over access. Some patient-
participants seemed well-versed in recent advances in big-data
usage and sharing practices. As one put it, “You know all the
world has become a data collection model, and sometimes
not all that data is used for the right purposes…sometimes
that could be a little scary, I guess, to think that if somebody
with ill intentions could get their hands on data” (P09).
Another alluded to the practice of ‘mosaicking’, where individ-
ual data sets are combined to analyze broader swaths of data
like “government combined with big industry and medical
pharma…” (P02). However, in contrast, a clinician admitted
that she did not have a concern with “de-identified genetic
data…and pooled resources” as long as it was for the purposes
of “understanding disease processes…” (C10).
Patient-participants were concerned that data might be
bought and used by government, industry, and advertisers
specifically. For example, one patient worried that “Even
though it’s supposed to be confidential…it doesn’t take
much for the head of Health and Human Services to say,
‘Yeah, we’re gonna look at all [the genetic data]. We’re
going to put them on a database and we’re gonna see what
we got here’” (P02). Concerns with private industry use
included that “depending on the company, they may get
greedy and…continue passing this information on…and
then…the whole confidentiality thing is down the toilet”
(P08); or “I feel like here at [the AMC], I get…what [the
genetic data is] being used for. At Merck or a huge pharma-
ceutical company…quite often their eyes are much more
focused on the profits of the company. So…that would be
where I would worry about the usage…” (P09).
Regarding concerns with advertising, one patient worried
that “when I’m online and I’m looking up bathing suits on
Macy’s and I click on the top and the bottoms, and then 5
minutes later an ad pops up for bathing suits at somewhere
else, I’m really not happy…And I don’t want [a pharmaceuti-
cal] company to do that to me because I’m none of their
business. My research is their business, but I’m not their
business” (P04). One clinician also confirmed this concern,
observing that the data should not be sold to see “who buys
what or Googles what” (C10).
All of that said, we found that our patient-participants
were actually generally more comfortable with the idea of
commercialization of their own data than their clinicians. For
example, whereas one patient stated “I would be completely
okay with that” (P05), her clinician worried that her patient
would have a negative response. Another patient stated that
“I wouldn’t have a problem with [commercialization] if
[industry is] doing research, too–or maybe they’re coming up
with a pill or vaccine or something that might help. Maybe
my genetic material might help with that? I’m completely
fine with that” (P07). And a third patient clearly stated “that
would be fine” (P08), whereas her clinician threated to take
herself off the study if she found out her patients’ data were
being commercialized. As this clinician reasoned,
…if you look at just the stuff in the media…the
Immortal Life of Henrietta [Lacks]… I would just say
that a good rule of thumb for me is that…if I read in
the newspaper one day that this happened at x, y, or
z University, and I’m sitting here at our university
thinking, well… they shouldn’t have done that, and
what were they thinking? And we would never do
that… And then we do something like that? I mean, I
would not want that [we sold patient materials to a
pharmaceutical company] on the front page of the
New York Times. If it’s going to look bad, and you’re
going to be embarrassed, then you just know it’s not
the right thing to do (C08).
Other patients and clinicians agreed on the potential bene-
fits of commercialization; as one patient put it, “I would
have no problem with that, and I would be very glad to
help” (P10), and her clinician concurred: “I think this data
should free flow much more than it already does…” (P10).
Investment of Profits
We also asked whether investment in cancer research, ver-
sus research more generally, would have an effect on will-
ingness to participate. A plurality of patients were
supportive of reinvesting profits back into cancer research
specifically: “I would be delighted…if they would do pre-
cisely that!” (P05); “that’s what I would hope you do with
the money…” (P07); “I think that’s wonderful…” (P11); and
“Absolutely, I won’t be doing anything with this data; you’re
Table 2. Informed consent form language
Topic Excerpt from consent form
Data sharing “Researchers can ask to study the
materials stored in the Biobank. This
includes researchers from the
[university], as well as from other
universities, the government, and
drug- or health-related companies.
Some researchers will be from the
U.S.; some may be from other
countries around the world. All of the
information collected about you will be
preserved and made available to
others for research. The researchers
and officials of the National Institutes
of Health will be responsible for
deciding how the data will be shared.”
Commercialization “This information may ultimately have
significant therapeutic or commercial
value. By agreeing to participate in this
study, you consent to such uses.”
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welcome to have it all!” (P10). However, two of our patient-
participants remained skeptical: “As good and as nice and
forthright as you guys are, I’d rather you guys not make a
profit off of research on me” (P06); and “I understand that’s
what you would want to do with any money you made off
us…[but] I wouldn’t want to be part of it…” (P09).
Several clinician-participants also felt positive about
reinvesting commercialization profits back in cancer research:
“I think that’s appropriate…as long as…the monies obtained
stay within the sequencing program to move the field for-
ward” (C07). Another pointed out that this is typically how
other types of research, such as cell line research, already
work. One clinician, however, remained staid in her objection
to commercialization across the board: “No, I would not [be
comfortable with reinvesting profits in cancer research]. I
think, again, it’s a means and an ends question… [just because]
the end product is lofty and good, does not mean that it’s
okay…to take any pathway there that you want” (C08).
Patient-participants were likewise overall supportive of the
prospect of investing commercialization profits back into
research generally (rather than just into oncology). One
patient agreed to investing in “any sort of expanding of knowl-
edge” (P05). Another said that as long as the research was
toward “helping humanity” and the researchers used the
money “to get smarter on this stuff” (P06), she would consent.
As another put it, “You guys make some amazing…diagnoses…
and they don’t necessarily have to do with cancer. I think that
your research is amazing, and the only way it could get even
more amazing is if you do it—and you have to do it! And you
can’t do it unless you have the tools you need” (P07).
Most of the cancer doctors, however, were skeptical about
investing profits derived from commercialization of their
patients’ data outside their own research area. One argued
that the reason she felt that way is because she believed that
was what her patients would assume: “[Investing profits
elsewhere is] problematic because these patients have com-
mitted to that department or that program. That’s what they
consented to, and that’s what they believe their biology
would go to” (C07). Another clinician argued that any profits
should be routed back to the original department because
they “put in the initial investment…” (C09). And, as a last
clinician joked, “we gotta pay my salary!” (C10).
Return of Information
A last area of analysis was how patient- and clinician-
participants would feel about return of some information,
such as ancestry information, from the private entity directly.
Six patients reported they would be comfortable with that,
and two reported discomfort. One patient enthusiastically
endorsed the idea: “That would be awesome and fun and
exciting. Yeah!” (P07). Another admitted “that’d be cool,”
but only if the information was relayed through the AMC as
an “honest broker” such that the outside entity never had
patient-identifying information (P04).
In contrast, clinicians were—again—more concerned
about this prospect than their patients. One clinician was
specifically worried about the return of ancestry information
being “just kind of thrown on afterwards, and not really for
helping these patients.” She argued that “This superfluous
information I would tend to avoid” (P07). Another pointed
out “that would be very alarming to me as a patient…”
because the informed consent form had already promised
that any data being commercialized would be de-identified
(which would obviate the ability of an outside organization
contacting the patient directly) (P11). And, as a last clinician
worried, “I hope we aren’t selling it to 23andMe!” (P04).
Possible Solutions
Although we did not prospectively ask our patient- and
clinician-participants about possible solutions to the con-
cerns elucidated above, several volunteered their thoughts
on the topic. Two patients and one clinician suggested that
the AMC put in place an oversight board to ensure transpar-
ency and to contract for acceptable future uses of data
before agreeing to commercialized. Two clinicians also
suggested modification of the informed consent form: either
that a separate informed consent form for commercialization
should be provided or that there should be an affirmative
opt-in check box for patients to indicate their wishes.
DISCUSSION
Our work demonstrates that at least some participants,
including both patients and clinicians, did not understand
that the consent process permitted the commercialization of
patient specimens or data, because they did not hear, read,
process, or retain such information. If institutions value
ensuring that participants in genetic research are adequately
informed, they will need to simplify or otherwise clearly
explain this conceptually to participants, particularly when it
comes to the complex and confusing nature of genetic data
commercialization.
The recent revisions to the Common Rule require that reg-
ulated researchers disclose whether biospecimens might be
used in the future for “commercial profit” [9]. MiOtoSeq
investigators in this study voluntarily extended this obligation
to genetic data. However, these disclosures may be of limited
value if relegated to a lengthy informed consent form, the
signing of which may imply little regarding the degree to
which the consenting individual was actually informed.
In addition, and despite the specification that their data
would be de-identified, most of our patient-participants
either expressed reservations with some aspect of commer-
cialization (e.g., discomfort with the very idea of anyone
“profiting” from their data) or stipulated conditions for the
use of their data or the profits derived thereof (e.g., that
profits should be reinvested back into research). Despite
these concerns, many patients indicated they would still be
comfortable with their data being sold to a private com-
pany. In fact, some patients were enthusiastic about such
an opportunity, perhaps in part motivated by altruism
rather than a desire for personal gain, as in prior work
exploring motivations for donating tissue to a biobank [21].
These responses indicate that patients have a strong inter-
est in whether their data are sold for profit, even when
those data are de-identified. This suggests that the disclo-
sure mandated by the Common Rule—which only applies
to identified biospecimens and neither de-identified bio-
specimens nor data—might be too narrow in scope to fully
assuage the concerns of participants. Somewhat
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predictably, our head and neck cancer clinician-participants
felt more strongly than our patient ones that profits derived
from data commercialization be invested back into head
and neck cancer research specifically; they were also pro-
tective of their patients receiving additional results (such as
ancestry) from a private company directly.
This study has limitations. First, as appropriate for an
exploratory qualitative design, the sample was small and
drawn from a single precision oncology sequencing study of
one disease site and might not be representative of patients
with cancer generally. In addition, patients with cancer com-
prise a special population and might be more willing to con-
tribute sensitive genetic data to research, given the serious
nature of their disease, than other patients [22, 23]. Also, we
originally designed our interview instrument to assess partici-
pant feelings regarding profit investment rather than
informed consent form comprehension; an explicit question
or knowledge test about the consent form may have rev-
ealed such misunderstandings to be more widespread. Given
that responses fell across a spectrum suggestive of heteroge-
neity, a larger, multisite evaluation of patients’ preferences
for, and comprehension of, genetic data commercialization is
still warranted to further explore these hypotheses.
Precision oncology researchers might hesitate to be thor-
oughly transparent regarding potential commercialization of
participants’ specimens and genetic data, particularly if they
are not legally required to do so, because of the concern that
enrollment rates may suffer. Indeed, past quantitative research
has indicated that the majority of participants are not comfort-
able with such use [5]. However this qualitative exploration
has demonstrated that patients with cancer (such as in preci-
sion medicine trials) might in fact be more comfortable with
commercialization than their practitioners assume. Additional
protections at the institutional level that exceed legal require-
ments, such as a data and specimen commercialization over-
sight committee [24, 25], might generate additional assurance
both to patients and cautious providers.
CONCLUSION
As various stakeholders continue to negotiate the terms of
academic and commercial engagement, the voices of
participants are critical to mitigate both dignitary harms such
as violations of privacy as well as a degradation of trust in the
research enterprise. Precision oncology participants did not
always understand that they had already “consented” to com-
mercialization of their specimens and data, and had additional
concerns about privacy and resultant profits. Moreover,
patients were generally more comfortable with commercializa-
tion than their clinicians were. These findings can be inte-
grated into a consent process designed to increase both
transparency and comprehension, as well as ensure that the
profits from patient data commercialization are reinvested in a
manner that both advances oncology research and encourages
engagement of patients.
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For Further Reading:
Jeffrey Peppercorn, Eric Campbell, Steve Isakoff et al. Patient Preferences for Use of Archived Biospecimens from
Oncology Trials When Adequacy of Informed Consent Is Unclear. The Oncologist 2020;25:78–86.
Implications for Practice:
This survey evaluated views of patients with cancer regarding the permissible use of stored biospecimens from cancer
trials when modern scientific methods are not well described in the original informed consent document. The vast
majority of patients support translational research and expect that any biospecimens they donate will be used to
advance knowledge. When researchers, policy makers, and those charged with research oversight debate use of stored
biospecimens, it is important to recognize that research participants have an interest in productive use of their blood,
tissue, or data, in addition to considerations of risks and the adequacy of documented consent.
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